BIODYNE Co., Ltd.

BIODYNE Co., Ltd.

KKRX:314930
5,220.00
KRW
+30.00
(+0.58%)
-9.05EPS
265.29BMarket Cap
Nov 18Next Earn
BIODYNE Co., Ltd.
KRX:314930
(Korea Stock Exchange)

Recent

price

5,220.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
159.75
998.45
206.64
157.74
127.28
396.04
27.21
178.83
239.32
143.65
Revenue per Share
17.45
-365.4
-102.4
-191.4
-367.2
182
-6.6
0.37
29
-9.05
Basic EPS, GAAP
8.52
-66.79
-295.79
-34.66
-46.36
33.2
-1.76
11.48
-163.68
-87.65
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
73.74
17.28
269.06
286.49
1,309.28
1,501.78
1,471.74
1,465.55
1,495.05
1,492.79
Book Value per Share
73.14
-290.95
-8.62
38.39
1,127.15
1,335.31
1,332.18
1,352.03
1,336.65
1,348.07
Tangible Book Value per Share
29
4
20
23
30
31
150
29
29
29
Basic Weighted Avg Shares
4,697
3,771
4,089
3,671
3,763
12,210
4,089
5,271
7,028
4,105
Sales/Revenue/Turnover
24.32
12.61
-41.52
-49.75
-62.25
54.73
-50.16
-32.82
9.28
-28.45
Operating Margin (%)
49
144
1,130
1,216
1,344
1,558
1,665
1,622
1,328
1,215
Depreciation Expense
513
-1,380
-2,026
-4,454
-10,857
5,611
-992
11
852
-259
Net Income, GAAP
15.84
- -
- -
- -
- -
23.82
- -
- -
- -
- -
Effective Tax Rate (%)
10.92
-36.6
-49.55
-121.34
-288.5
45.96
-24.26
0.2
12.12
-6.3
Profit Margin (%)
1,229
-7,972
-4,735
1,112
20,675
21,661
20,530
21,213
17,830
17,037
Working Capital
- -
- -
6,860
6,744
12
2
- -
- -
- -
- -
LT Debt
1,802
422
6,576
7,002
38,498
44,159
43,382
43,200
44,069
44,003
Total Equity
- -
- -
- -
- -
- -
12.19
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
13.57
- -
- -
- -
- -
Return on Capital (%)
- -
-124.07
-57.91
-65.61
-47.72
13.58
-2.27
0.02
1.95
-0.6
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
ST Debt
4
9
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
29
29
29
Market Capitalization
403,242
350,773
265,291

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Mar'26
Jun'26
Total Current Assets
21,675
18,612
17,416
Cash, Cash Equivalents & STI
19,657
15,223
14,753
Accounts Receivable, Net
276
2,145
1,720
Inventories
784
511
508
Total Current Liabilities
774
468
379
Payables & Accruals
- -
- -
- -
ST Debt
4
9
6
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
92.87%
2.01%
Free Cash Flow
- -
-395.88%
-1,520.97%
Net Income, GAAP
- -
1,516.05%
7,806.97%
Sales/Revenue/Turnover
- -
44.54%
33.32%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,106
1,232
1,520
1,413
5,271
2025
917
1,791
859
- -
7,028
2026
867
587
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-7
5
-13
15.03
0.37
2025
-15
-4
0.44
- -
29
2026
5.27
-11
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
BIODYNE Co., Ltd. is a South Korea-based medical biotechnology company specializing in the research, development, manufacturing, and commercialization of liquid-based cytology (LBC) systems, diagnostic reagents, and automated medical devices for cancer screening and cellular pathology diagnostics. Founded in 1999 and headquartered in Seoul, South Korea, the company operates within the in vitro diagnostics and medical devices industry, serving hospitals, pathology laboratories, screening clinics, and research institutions across domestic and international markets, including Asia, Europe, and the Americas. BIODYNE provides end-to-end cytology solutions organized across core product categories: automated liquid-based cytology preparation instruments, including the PATHPLORER series (such as PATHPLORER AUTO, PATHPLORER 4.7, PATHPLORER 4.63, and PATHPLORER ECO) and legacy Cellprep platforms, which utilize patented Blowing Technology to deposit diagnostic cells onto microscope slides in uniform monolayers via controlled air pressure; specialized cell preservation solutions and liquid-based reagents formulated for cell fixation, sample transport, and diagnostic staining for gynecological and non-gynecological testing; specialized cytology consumables, including sample preservation vials, membrane filters, coated glass slides, and transfer tips; and advanced cell collection devices, notably the EarlyPap self-sampling cervical collection brush developed with Bloom and Grip technology for speculum-free cytology and HPV/STD testing. In recent developments, BIODYNE transitioned into commercial revenue generation under its exclusive 20-year global technology licensing and supply partnership with Roche Diagnostics, which incorporates BIODYNE's proprietary Blowing Technology into the Roche VENTANA SP400 automated liquid-based cytology system. Following the launch of the VENTANA SP400 in Japan in 2025, BIODYNE commenced mass shipments of dedicated gynecological consumables and collected its final development milestone payment, establishing a recurring income structure based on instrument royalties and ongoing consumable supplies. In addition, the company has expanded production capabilities and pursued international regulatory certifications for its EarlyPap self-collection brush to support global cancer screening initiatives.